New hope for rare blood cancer: QUANTUM trial tests targeted therapy after transplant
NCT ID NCT07605416
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times
Summary
This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy or teclistamab. The goal is to see if teclistamab can kill any remaining cancer cells and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alliance for Clinical Trials in Oncology
RECRUITINGChicago, Illinois, 60606, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- New transplant recipe aims to tame Graft-Versus-Host disease
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- New drug cocktail aims to beat myeloma
- Experimental Dual-Target CAR-T therapy takes aim at Hard-to-Treat plasma cell cancers
- New cocktail aims to tackle tough myeloma cases